# Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

> **NCT02866383** · PHASE2 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer
- Metastatic Biliary Tract Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02866383
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2022-01-05
- **Final completion:** 2022-11-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2023-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866383, "Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02866383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*